Active Pharmaceutical Ingredients and Excipients: The Distributor’s Role 

TL;DR

Active pharmaceutical ingredients (APIs) are the biologically active substances that make a drug work. Excipients are the inactive components that make it manufacturable, stable, and deliverable. Between manufacturers and formulators, specialty distributors play a critical — and often underestimated — role: ensuring quality-compliant sourcing, regulatory traceability, technical expertise, and supply chain resilience across global markets.

What Are Active Pharmaceutical Ingredients (APIs)? 

An active pharmaceutical ingredient is defined by ICH Q7 as "any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product." Its function is to furnish pharmacological activity — in the diagnosis, cure, treatment, or prevention of disease, or to affect the structure and function of the body. 

APIs exist in multiple physical states — solid powders, crystals, liquids — and are classified into two broad categories: 

• Synthetic APIs — produced through chemical synthesis, the most common category in modern medicine 

• Natural APIs — extracted from plant, animal, or microbial sources and subsequently purified 

Every API is subject to strict regulatory oversight. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate compliance with current Good Manufacturing Practices (cGMP), covering documentation of manufacturing processes, validation of analytical methods, and submission of regulatory filings. The WHO prequalification process further assesses API Masterfiles and inspects manufacturing sites to confirm adherence to international standards. 

What Are Pharmaceutical Excipients? 

Pharmaceutical excipients are all substances present in a finished drug formulation other than the active ingredient. Though historically described as "inactive," this characterisation is increasingly challenged by science.

As noted in a peer-reviewed study published in PMC (National Institutes of Health):

"The functional roles of pharmaceutical excipients include modulating bioavailability and solubility of APIs, increasing the stability of APIs in the dosage form, maintaining the osmolarity and/or pH of liquid formulations." 

In fact, excipients now make up 80–90% of the finished pharmaceutical product by mass, according to research published in the International Journal of Pharmaceutical Investigation (2025). Their selection is a formulation-critical decision — not a commodity choice.

Main functional categories of excipients 

Excipients are not interchangeable. A historical case illustrates this precisely: in the 1960s, replacing calcium sulphate with lactose in phenytoin capsules — a substitution considered harmless — caused a 4.5-fold increase in serum drug concentration, resulting in toxicity in epileptic patients in Australia. The European Pharmaceutical Review documented this case as a landmark example of why excipient selection demands rigorous scientific evaluation.

Why Excipient Quality Matters — The Regulatory Framework 

Excipients must meet pharmaceutical-grade standards, defined by major pharmacopoeias: 

• USP–NF (United States Pharmacopeia – National Formulary),
• European Pharmacopoeia (Ph. Eur.), 11th Edition,
• ICH Q8(R2) — Pharmaceutical Development: guidance on quality by design (QbD) and functionality-related characteristics (FRCs) of excipients.

Regulatory compliance for excipient manufacturers has increased significantly in recent years. According to the International Pharmaceutical Excipients Council (IPEC), the cost of regulatory compliance for excipient manufacturers rose by over 30% in the past five years, as agencies globally tighten oversight to ensure patient safety and product efficacy.

In the European Economic Area and the UK, Good Distribution Practice (GDP) certification is mandatory for all wholesale distributors of medicines and APIs. The EMA defines GDP as "a set of fundamental standards that wholesale distributors must adhere to in order to uphold the quality and integrity of pharmaceuticals throughout the supply chain."

The Pharmaceutical Excipients Market: A Growing Sector 

The global pharmaceutical excipients market reached approximately USD 10.4–10.7 billion in 2024–2025, with multiple independent market research firms projecting sustained growth: 

• Mordor Intelligence projects the market will reach USD 15.71 billion by 2030 at a CAGR of ~7.9%
• Market Research Future forecasts growth to USD 21.16 billion by 2035 at a CAGR of ~7.0%
• Europe led with approximately 37–38% of global revenue in 2024

• Europe led with approximately 37–38% of global revenue in 2024 

Key growth drivers include: 

• Rising demand for biologics and biosimilars, requiring protein-compatible stabilisers
• Expansion of generic drug production following major patent expirations
• Increasing complexity of controlled-release and parenteral formulations
• Regulatory pressure toward traceable, sustainable supply chains
• Growing adoption of AI-assisted excipient selection in formulation development

The Distributor's Role in the Pharmaceutical Supply Chain 

Safic-Alcan's Approach to Pharmaceutical Distribution 

Safic-Alcan is a specialty chemical distributor with over 75 years of experience, operating across more than 90 countries. In the pharmaceutical sector, Safic-Alcan acts as a value-added distributor — not a commodity trader.

Our pharmaceutical offering covers:

• Active pharmaceutical ingredients (APIs) — sourced from qualified manufacturers, with full GMP/GDP compliance documentation
• Pharmaceutical excipients — across all functional categories (binders, fillers, lubricants, coating agents, stabilisers, surfactants)
• Excipients for adjacent regulated sectors — nutraceuticals, cosmetics (INCI-compliant actives), and food & beverage (E-number additives, functional ingredients)

FAQ : A specialty distributor's role

What is the difference between an API and an excipient?

An API (active pharmaceutical ingredient) is the substance that produces the intended therapeutic effect in a drug — it is the biologically active component. An excipient is every other ingredient in the formulation: binders, fillers, lubricants, coatings, stabilisers, etc. Excipients have no direct pharmacological effect but are essential for manufacturability, stability, bioavailability, and patient acceptability.

Why does excipient quality matter so much?

Excipients are not inert commodities. Their physicochemical properties directly influence drug release, bioavailability, and stability. A change in excipient grade or supplier can alter a drug's performance — sometimes with serious clinical consequences. Regulatory agencies require full qualification and documentation of all excipients used in pharmaceutical products.

What regulations govern API and excipient distribution?

Distributors of APIs and excipients must comply with Good Distribution Practice (GDP) guidelines — mandatory in the EU/UK (EMA guidelines, Directive 2001/83/EC) and enforced in the US through the Drug Supply Chain Security Act (DSCSA). GDP requires quality management systems, full traceability, controlled storage conditions, and supplier qualification programmes.

What is the role of a specialty distributor vs. a direct manufacturer relationship?

A specialty distributor provides access to a curated portfolio of qualified suppliers, regulatory documentation, local stock, and technical expertise — without the minimum order quantities and lead times typically imposed by large manufacturers. For formulators working with multiple ingredients across multiple markets, a distributor simplifies procurement, consolidates compliance documentation, and provides application support that manufacturers rarely offer directly.

How does Safic-Alcan support pharmaceutical formulators?

Safic-Alcan provides qualified APIs and excipients with full GMP/GDP compliance documentation, technical application support, regulatory dossiers (CoA, DMF, CEP), and access to a global supplier network across 90+ countries. Our teams combine sector-specific expertise in pharma, nutraceuticals, cosmetics, and food — enabling cross-sector formulation insights for complex development projects.

What is the pharmaceutical excipients market outlook?

The global pharmaceutical excipients market was valued at approximately USD 10.4–10.7 billion in 2024–2025 and is projected to grow at a CAGR of 5.75–7.93% through 2030–2035, driven by biologics, generic drug expansion, advanced drug delivery systems, and tightening regulatory requirements for supply chain traceability.